A range of mechanisms are observed, including down‐regulation of activatory receptors on NK cells, reduction of NK ligands on the tumour and decreased production of the potent NK‐stimulatory cytokine IL‐15, secondary to acquisition of the FLT3 mutation (Mathew et al., 2018). The gene discussed is FLT3; the disease is neoplasm.